Minirin (Desmopressin Acetate)

Desmopressin acetate mimics the natural hormone vasopressin and selectively activates V2 receptors in the kidney’s collecting ducts. This activation raises intracellular cAMP, causing aquaporin‑2 water channels to move to the cell surface, which increases water reabsorption and consequently reduces the volume of urine produced.

The dose of Minirin is individualized. A qualified prescriber determines the appropriate amount, frequency, and duration based on the patient’s specific condition, age, renal function, and response to therapy. Patients should follow the prescribing information provided by their healthcare professional.

Safety data for Minirin in pregnancy and lactation are limited, and the pregnancy category is listed as unknown. Healthcare providers should weigh potential benefits against possible risks and discuss these considerations with the patient before initiating therapy.

To request Minirin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Minirin (desmopressin) is a synthetic vasopressin analogue with high selectivity for V2 receptors, offering a longer duration of action and fewer vasoconstrictive effects than natural vasopressin (Pitressin). This makes it preferable for chronic management of diabetes insipidus and nocturnal enuresis, while other ADH analogues may require more frequent dosing or have greater cardiovascular side‑effects.

Minirin nasal spray should be stored at ambient temperature, below 25 °C. Keep the device in its original packaging, protect it from moisture and direct sunlight, and ensure the cap is tightly closed when not in use to maintain product stability.

Minirin is delivered as a metered‑dose nasal spray. The patient should gently blow the nose, insert the tip into one nostril, and press the actuator to release a single spray while breathing normally. The dose may be repeated in the opposite nostril if prescribed, and the device should be cleaned according to the manufacturer’s instructions.

The most critical safety concerns are severe hyponatremia, which can lead to seizures, cerebral edema, or water intoxication. Patients should be monitored for rapid weight gain, confusion, headache, or vomiting, and serum sodium levels should be checked regularly, especially during the initial weeks of therapy.

Minirin is contraindicated in individuals with known hypersensitivity to desmopressin, uncontrolled hyponatremia, severe renal impairment, or conditions predisposing to fluid overload such as uncontrolled heart failure. Caution is also advised for patients with chronic lung disease, adrenal insufficiency, or those taking medications that increase the risk of hyponatremia.